Education
About Us
Working with TipRanks
Follow Us
Kane Biotech Inc (TSE:KNE)
:KNE
Earnings Data
Report Date
Mar 19, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
―Last Year’s EPS
<0.01Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth driven by new product sales and service revenue streams. Strategic partnerships, regulatory approvals, and expansion into new markets were noted as positive developments. However, increased operating expenses and a decrease in cash reserves were challenges mentioned. Overall, the positive developments notably outweigh the drawbacks.Company Guidance
Significant Increase in Product Sales
Product sales for Q3 2024 were $598,000 compared to $4,000 in Q3 2023, primarily due to the first commercial sales of revyve Antimicrobial Wound Gel to the U.S. distributor ProgenaCare.
Introduction of New Revenue Streams
Product services revenue for Q3 2024 was $685,000, derived from animal health, manufacturing, and quality control services after the sale of STEM Animal Health subsidiary.
Improved Financial Performance
Total revenue for Q3 2024 was $1,283,000 compared to $27,000 in Q3 2023. Gross profit was $559,000 compared to $23,000 in the previous year.
Strategic Partnerships and Certifications
Kane Biotech received ISO 1345:2016 MDSAP quality certification and secured a licensing agreement with Omni Bioceutical Innovations for the DermaKB line.
Regulatory Approvals and Expansion
Received FDA approval to increase the dosage allowance for revyve Antimicrobial Wound Gel and Health Canada approval for the same product. Distribution agreements were announced for international markets.
Funding and Development Initiatives
NRC IRAP funding received for revyve Antimicrobial Wound Gel and the development of DispersinB Wound Gel, with participation from a major wound care company.
Acquisition of FB Dermatology
The agreement to acquire FB Dermatology is expected to enhance commercial reach and technology portfolio, including products like LumiHeal and Kleresca.
TSE:KNE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TSE:KNE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 28, 2025 | C$0.03 | C$0.04 | +33.33% |
Aug 28, 2025 | C$0.04 | C$0.04 | 0.00% |
May 29, 2025 | C$0.06 | C$0.05 | -16.67% |
Apr 28, 2025 | C$0.10 | C$0.08 | -20.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Kane Biotech Inc (TSE:KNE) report earnings?
Kane Biotech Inc (TSE:KNE) is schdueled to report earning on Mar 19, 2026, TBA (Confirmed).
What is Kane Biotech Inc (TSE:KNE) earnings time?
Kane Biotech Inc (TSE:KNE) earnings time is at Mar 19, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSE:KNE EPS forecast?
Currently, no data Available